Johns Hopkins ABX Guide
Oteseconazole
INDICATIONS
FDA
FDA
- Oteseconazole (Vivjoa) is an FDA-approved azole antifungal to reduce the incidence of recurrent vulvovaginal Candidiasis (RVVC) in women not of child-bearing potential.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: November 13, 2023
Citation
Dzintars, Kathryn. "Oteseconazole." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540783/all/Oteseconazole.
Dzintars K. Oteseconazole. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540783/all/Oteseconazole. Accessed June 16, 2024.
Dzintars, K. (2023). Oteseconazole. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540783/all/Oteseconazole
Dzintars K. Oteseconazole [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 June 16]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540783/all/Oteseconazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oteseconazole
ID - 540783
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2023/11/13/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540783/all/Oteseconazole
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
